Radio 223 en cáncer de próstata resistente a la castración

Loizaga-Iriarte, Ana; Camargo Ibargarai, Isabel; Senarriaga-Ruiz de la Illa, Nerea; Lacasa-Viscasillas, Isabel; Unda-Urzaiz, Miguel.
Arch. esp. urol. (Ed. impr.) ; 71(8): 696-703, oct. 2018.
Artículo en Español | IBECS (España) | ID: ibc-178747

Documentos relacionados

  1. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
  2. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.
  3. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
  4. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
  5. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
  6. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
  7. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
  8. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
  9. Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
  10. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.